IMU Biosciences, a UK biotechnology company working to analyse the immune system with AI and multi-omic technology, has closed an oversubscribed financing round that brings its total Series A to over $53 million. The London-based company was founded by a team of experimental immunologists and computational biologists drawing on research from the Francis Crick Institute and King's College London. Its goal is to build what it says is the world's largest immune dataset, and to use it to improve how disease is understood, diagnosed, and treated.
The immune system is involved in almost every major disease area, from cancer to transplantation to autoimmune conditions. Despite that, the tools used to study it have long been limited. Most can detect only broad biological signals, without the detail needed to make precise clinical decisions for individual patients. Investment in the field reflects how much that gap matters. The global precision immunology market was valued at $24.6 billion in 2025 and is projected to reach $71.3 billion by 2032, according to research published in January 2026, with growth driven by rising rates of immune-mediated disease and increasing use of biomarker-guided treatments.
The latest round was co-led by IQ Capital and Molten Ventures, with participation from the British Business Bank and Meltwind, alongside existing investors. IMU has now raised $60 million in total.
The immune system contains billions of cells that interact differently in each person. Standard diagnostic tools capture only a small part of that activity. IMU's platform analyses a 2-millilitre blood sample and generates over 100 million immune data points, classifying 2,500 distinct immune cell subtypes in real time. The company refers to this approach as HD Immunology, meaning high-definition immunology, and describes it as the most detailed immune picture assembled at clinical scale.
Two underlying methods make this possible. Multi-omic analysis looks at multiple layers of biological information at once, going beyond a single gene or protein to study how different systems in the body interact. Machine learning models then process the resulting data far faster and at greater resolution than any manual analysis could achieve. Together, the two methods are intended to support a universal standard for immune profiling, one that could help identify new disease mechanisms, monitor how patients respond to treatment, and predict whether a particular therapy is likely to work for a particular person.
"When we first invested in IMU in 2024, we believed deep immune profiling combined with AI could unlock something genuinely transformative in precision medicine. Our participation in this round reflects what we've seen since: a team that executes and a platform that delivers. The immune system sits at the heart of almost every disease; a company that can interrogate it at this resolution has the potential to redefine how we match the right treatment to the right patient at the right time. We're proud to be IMU's largest shareholder and delighted to welcome IQ Capital and the British Business Bank as investors to the round, their support is a further corroboration of what IMU is building. We're excited about what comes next." — Dr Inga Deakin, Partner at Molten Ventures
The new capital will go toward three main areas: expanding operations, developing the clinical platform and its infrastructure, and advancing active clinical programmes. IMU has already built a dataset covering samples from over 25,000 people, which it says is unmatched globally in terms of resolution and depth.
On the clinical side, the company is running programmes in two transplantation areas. In hematopoietic stem cell transplantation, commonly known as HSCT, the challenge is predicting how well a donor's stem cells will work in a recipient's body. IMU is working on a screening tool to improve that prediction before a transplant takes place. In solid organ transplantation, the focus is on identifying patients at risk of rejecting a transplanted organ before rejection occurs. Both areas involve clinical decisions that doctors currently have limited data to guide.
IMU is also part of MANIFEST, a UK research consortium studying why some cancer patients respond well to immunotherapies while others do not. Immunotherapy works by helping the body's own immune system fight cancer, but the results vary widely between patients. Understanding why is one of the harder problems in oncology today, and IMU's platform is being applied to it at a large scale.
IMU was built on research developed over more than a decade at the Francis Crick Institute and King's College London. Dr John Baker is Chief Executive Officer. Dr Adam Laing, co-founder, serves as Chief Scientific Officer.
The core problem IMU is trying to solve is that most immune tests only show a fragment of what the immune system is doing. The platform addresses this by identifying 2,500 distinct immune cell subsets from a single blood draw, then applying machine learning to find patterns that are clinically meaningful. The intended output is practical: insights that clinicians can use when making decisions about diagnosis, treatment selection, or monitoring a patient's progress over time.
Dr Baker has spoken about the difficulty that has defined the field so far. The immune system, despite its central role in human health, has remained poorly understood because the available tools have been fragmented, mechanistic, and low-resolution. IMU's platform is aimed at providing a more complete picture across a wide range of immune-mediated diseases.
The company operates from London's Wood Wharf and works with partners in clinical research, pharma, biotech, and diagnostics.
The Series A was co-led by Molten Ventures, a European venture capital firm investing in high-growth technology companies, and IQ Capital, a deep tech venture capital firm that has backed over 250 founders across Europe since 2005. IQ Capital invests from pre-seed through to Series A, with the ability to follow on with further capital through later-stage funds.
The British Business Bank, a development bank wholly owned by the UK government, joined the round alongside Meltwind. The bank's stated mission is to help smaller businesses access the finance they need to grow in the UK, and its life sciences team highlighted IMU's combination of proprietary data and biological insight as central to its decision to invest.
"With the world's largest immune dataset and proprietary machine learning analytics, IMU is pioneering research to realise the huge value of health data, creating better insights for clinicians and improved outcomes for patients." — Dr Alex Wilson, Partner at IQ Capital
